Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | DDO | Q99489 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30549097 | 1.00 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL545302 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL10617 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL1582138 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL248620 | 0.75 | BRD4 (1.00) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL1238471 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL1394237 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL4460778 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL10481645 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 | |
| SCHEMBL6283609 | 0.75 | DAO (0.60) | DAOBRD4DDOKDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021997-A1 | NEW MAP4K1 INHIBITORS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-01-30 | — | — | WO | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| CN-107951950-A | A kind of pharmaceutical composition for treating amenorrhoea and preparation method thereof | 程庸堂 | 2018-04-24 | — | — | CN | claimed |
| CN-101410468-B | Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups | CABOT CORP | 2012-04-11 | — | — | CN | claimed |
| CN-101747267-B | Method for synthesizing 4-substituted-3-chlorine-2-carbostyril | UNIV SOUTHWEST | 2011-07-13 | — | — | CN | claimed |
| CN-101747267-A | Method for synthesizing 4-substituted-3-chlorine-2-carbostyril | UNIV SOUTHWEST | 2010-06-23 | — | — | CN | claimed |
| CN-101410468-A | Inkjet ink compositions comprising polymeric dispersants having attached chromophore groups | CABOT CORP (US) | 2009-04-15 | — | — | CN | claimed |
| CN-1958001-A | Medication for treating high blood pressure | CHEN QINIAN (CN) | 2007-05-09 | — | — | CN | claimed |
| CN-1663591-A | Hypertension-treating medicine | CHEN QINIAN (CN) | 2005-09-07 | — | — | CN | claimed |
| CN-1167433-C | Medicine for treating acne and its preparing process | 王宗宽 | 2004-09-22 | — | — | CN | claimed |
| EP-0971712-A1 | COMPOSITIONS FOR THE INHIBITION OF BONE RESORPTION | Smith & Nephew plc (GB) | 2000-01-19 | — | — | EP | claimed |
| WO-1998035674-A1 | COMPOSITIONS FOR THE INHIBITION OF BONE RESORPTION | SMITH & NEPHEW PLC (GB) | 1998-08-20 | — | — | WO | claimed |
| EP-4674415-A2 | AZAQUINOLINES AS INHIBITORS OF CD38 | Boehringer Ingelheim International GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4284511-B1 | AZAQUINOLINES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2025-07-16 | — | — | EP | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| CN-1165655-A | Method of treating conditions with estrogen agonists | PFIZER (US) | 1997-11-26 | — | — | CN | disclosed |
| CN-1062906-A | The preparation method of 8-chloroquinolone derivatives | DAIICHI SEIYAKU CO (JP) | 1992-07-22 | — | — | CN | disclosed |
| US-5093515-A | Intermediate for quinolone carboxylic acid bactericide | ASAHI GLASS COMPANY LTD. (JP) | 1992-03-03 | — | — | US | disclosed |
| CN-1035433-A | PHARMACEUTICAL GRANULATE | GIST BROCADES NV (NL) | 1989-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | DAO 1582/4885BRD4 4849/4885DDO 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.